ERBB2 and breast cancer: VEGFC is significantly overexpressed in HER2+ breast cancer relative to basal breast cancer in TCGA (Fig. 6a, p-value of 0.005) and in HER2 + breast cancer relative to all other subtypes in METABRIC data (Fig. 6b, p-value of 4 × 10−6).